GYNECOLOGIC CANCERS

Anlotinib appeared safe with a manageable toxicity profile as treatment of patients with recurrent advanced cervical cancer in a phase 2 study.

Mansoor Raza Mirza, MD, discusses the final survival data from the randomized phase 2 NSGO-AVANOVA2/ENGOT-OV24 study, which evaluated the combination or niraparib plus bevacizumab versus niraparib alone in recurrent platinum-sensitive ovarian cancer.

Statistically significant improvements in time to second progression or death, or PFS2, was demonstrated in the bevacizumab/niraparib combination, as well as other positive clinical outcomes.

"In this trial, [mirvetuximab soravtansine] was combined with bevacizumab for a broader segment of recurrent ovarian cancer patients, regardless of platinum status."

Despite missing the primary end point of progression-free survival improvement, cediranib and olaparib demonstrated comparable activity with platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer.

Brian M. Slomovitz, MD, discusses the some of the subcategories of endometrial cancer and how the make a difference for patients’ treatment.

"It is a proof of concept of the efficacy of an immunotherapy in [patients with] gestational trophoblastic tumors , confirming the rationale we had."

Bradley J. Monk, MD, FACS, FACOG, discusses the remaining challenges in conducting clinical trials for patients with cervical cancer.

Encouraging survival outcomes were seen with trametinib in patients with low-grade serous ovarian cancer treated in a phase II/III clinical trial.

In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed the importance of molecular testing in ovarian cancer and how the treatment landscape will continue to evolve in tailoring treatment to patients based on the biology of their tumors, which was the topic of his lecture at the 2020 Society for Gynecologic Oncology (SGO) Annual Meeting.

Shannon N. Westin, MD, MPH, FACOG, discusses the evolving role of immunotherapy as treatment of patients with endometrial cancer.

"This approval is an important step forward in the treatment of ovarian cancer. In my opinion, maintenance treatment with niraparib should be considered an option for appropriate patients who responded to first-line platinum-based chemotherapy versus active surveillance."

In an interview with Targeted Oncology, Charlotte Sun, DrPH, MPH, discussed the findings from 2 abstracts from the 2020 SGO Annual Meeting on patient preferences for maintenance therapy in ovarian cancer and how these findings can be applied to practice in the community oncology setting.

"Adavosertib demonstrated promising preliminary clinical activity in patients with unselected uterine serous cancer."

Ross F. Harrison, MD, discusses the out-of-pocket costs for patients with ovarian cancer receiving PARP inhibitor treatment.

“There are limited treatment options for women with advanced or recurrent endometrial cancer, and prognosis of these patients is poor. The results observed in the GARNET trial indicate the potential of dostarlimab to offer a new treatment option for women with this challenging disease.”

"We are seeing clinically meaningful monotherapy activity of DKN-01 in heavily pre-treated endometrial cancer and carcinosarcoma populations, including a complete response, a partial response, and durable tumor reductions in many patients. In combination with paclitaxel, DKN-01 is generating durable responses and disease control in paclitaxel-experienced patients."

"The approval of our HPV test for the cobas 6800 and 8800 Systems enables molecular laboratories to achieve the efficiency and scale they need to meet the demands of high-volume cervical screening programs..."

Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. As such, olaparib failed to demonstrate a significant improvement in survival over chemotherapy.

Niraparib was granted Priority Review in China as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, by the National Medical Products Administration.

A 59-Year Old Woman With Stage IIIC Ovarian Cancer

In the phase III VELIA trial, the addition of veliparib to frontline induction chemotherapy expanded the number of complete responses and CA-125 responses in patients with high-grade serous ovarian cancer compared with chemotherapy alone, according to results from an exploratory analysis.